Other interesting perspectives would be the assessment of KRAS MAF changes in cfDNA of NSCLC patients treated with the novel targeted therapies such as the KRAS G12C specific inhibitor and the application of next-generation sequencing to track other tumor-specific co-mutations with potential prognostic significance in plasma samples. This evidence concerns the gene KRAS and non-small cell lung carcinoma.